With the complete separation of the Consumer Health segment, J&J (JNJ) is now a two-sector company focused on the Pharmaceutical and MedTech fields.

Johnson & Johnson is cutting its drug development efforts for infectious diseases. It hasn't said anything about ceasing sales of its products on the market.

3M and Johnson & Johnson have been increasing their dividend payments for decades. They offer above-average dividend yields, with 3M paying as much as 6%.

Three of Johnson & Johnson's blockbusters are on Medicare's price negotiation list. Drugmakers have filed court cases fighting the government's plan to directly negotiate prices.

Dividend stocks provide essential passive income for many investors. For those heading into retirement, this is especially true.

Johnson & Johnson (JNJ) on Wednesday released its first earnings forecast as a standalone pharmaceutical and medical devices company, estimating double-digit growth in earnings this year.

Johnson & Johnson and Indian drugmaker Lupin will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, a global anti-tube...

Johnson & Johnson (NYSE:JNJ) has released new financial results for previous quarters that strip out the consumer-health unit that was recently hived off into a new company called Kenvue. J&J, whic...

Johnson & Johnson maintains its quarterly dividend of $1.19 a share after spinning out consumer-health company Kenvue, although it lowers its earnings and sales projections.

J&J (JNJ) submits a supplemental new drug application to the FDA for full approval of Balversa to treat urothelial carcinoma.

The Biden administration says 10 prescription drugs will be subject to price negotiations with Medicare. The White House says some prices could be cut in half.

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

J&J's (JNJ) FDA filing is based on a late-stage study showing that treatment with Rybrevant plus chemotherapy improved progression-free survival in certain NSCLC patients.

Small investors earned a nice payday of more than $1,000 if they tendered 99 shares of stock in the swap, which expired last week.

Johnson & Johnson recently completed the Kenvue spinoff. We outline the impacts on its dividend payouts from this spinoff. I analyzed its dividend payout both using simple payout ratios and also us...